Key result
ACE inhibitors and ARBs slow chronic renal disease progression in hypertension.
Why the study?
Hypertension contributes to the progression of chronic renal disease through multiple mechanisms, with a pronounced effect in African-Americans who have higher prevalence of hypertension and end-stage renal disease.
Do ACEIs and AT II blockers reduce the progression of chronic renal disease in patients with hypertension?
Do ACEIs and AT II blockers reduce the progression of chronic renal disease in patients with hypertension?
ACE inhibitors and angiotensin II receptor blockers play a major role in halting the progression of chronic renal disease associated with hypertension.
Answers are grounded in this paper and cite their sources.
May support ACEI/ARB use to slow hypertensive CKD progression; leaves open need for updated RCTs.
Hypertension leads to renal disease through a series of mechanisms that seem to be exaggerated in African-Americans, who have a higher prevalence of both hypertension and end-stage renal disease than whites. Renal disease itself leads to hypertension, which in turn can contribute to progression of renal disease. Although there are numerous mechanisms involved in the process of renal disease progression, the renin-angiotensin system plays a major role as determined by the beneficial response to angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (AT II blockers) of reduced rate of progression in a variety of clinical and experimental renal diseases. Macromolecular trafficking across the glomerulus leading to proteinuria plays a significant role in progression of chronic renal disease. Reversal of this abnormality and reduced stress on capillary walls may be the major mechanisms of beneficial action of ACEIs and AT II blockers in halting renal disease progression.
No takes yet. Share an insight, caveat, or question.
Manuel Martinez-Maldonado (2001) conducted a review in Hypertension and chronic renal disease. Hypertension was evaluated. Hypertension contributes to chronic renal disease progression, a process that can be mitigated by ACE inhibitors and angiotensin II receptor blockers.
Synapse has enriched 10 related papers. Consider them for comparative context: